Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 6 art units • 17 examiners • 0 of 19 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
Ionis Pharmaceuticals Inc. maintains a robust prosecution profile with 19 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 17 distinct examiners and 6 distinct art units, indicating a broad and active portfolio. POLIAKOVA-GEORGAN, EKATERINA is the busiest examiner, currently managing 3 pending office actions.
The use of 17 distinct examiners for those matters shows a high degree of decentralization, which can mitigate the risk of any single examiner's bias. However, the concentration of the 19 pending office actions within 6 distinct art units suggests that the company's innovations are focused on specific therapeutic or technical areas. This structure allows for some specialization in prosecution strategy across those units.
Practitioners should monitor the 3 pending office actions under POLIAKOVA-GEORGAN, EKATERINA, as this examiner has the most significant individual impact. The examiners will likely provide a wide range of feedback, requiring a versatile legal team to manage the matters. The units involved will each have their own unique standards and prior art landscapes to navigate.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (32%) |
| §112 only | 1 (5%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 4 (21%) |
| Multi-statute (no §101) | 7 (37%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 3 | 64.0% | +18.0% |
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
| WHITEMAN, BRIAN A | 1 | 68.5% | +16.7% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| SHIN, DANA H | 1 | 27.0% | +27.0% |
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998141 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | ROSSI, JULIA ANNE LORRAIN | 67d overdue |
| 18569084 | MODULATION OF NOX4 EXPRESSION | VANHORN, ABIGAIL LOUISE | — |
| 18448392 | Selective Antisense Compounds and Uses Thereof | SHIN, DANA H | — |
| 18264705 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | RYAN, DOUGLAS CHARLES | — |
| 18358591 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | MEYERING, SHABANA SHABBEER | — |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 17908135 | COMPOUNDS AND METHODS FOR MODULATING KCNQ2 | CHONG, KIMBERLY | — |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443619 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | VYAS, KEYUR ANILKUMAR | 282d overdue |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | POLIAKOVA-GEORGAN, EKATERINA | 10d overdue |
| 18262438 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | KONOPKA, CATHERINE ANNE | 8d overdue |
| 18247567 | METHODS FOR REDUCING APOCIII EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 4d overdue |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | TATGE, LEXUS MARC | 13d |
| 18431253 | Modulators of Complement Factor B | WHITEMAN, BRIAN A | — |
| 18569084 | MODULATION OF NOX4 EXPRESSION | VANHORN, ABIGAIL LOUISE | — |
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | — |
| Art Unit | Apps |
|---|---|
| 1637 | 8 |
| 1635 | 5 |
| 1615 | 1 |
| 1636 | 1 |
| 1682 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443619 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 282d overdue | Pending | Feb 16, 2024 |
| 18431253 | Modulators of Complement Factor B | WHITEMAN, BRIAN A | — | §112DP | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18569084 | MODULATION OF NOX4 EXPRESSION | VANHORN, ABIGAIL LOUISE | — | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112DPOther | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18448392 | Selective Antisense Compounds and Uses Thereof | SHIN, DANA H | 1635 | DP | Final Rejection | — | Pending | Aug 11, 2023 |
| 18264705 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | RYAN, DOUGLAS CHARLES | 1635 | §103§112 | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | TATGE, LEXUS MARC | 1637 | §103 | Non-Final OA | 13d | Pending | Jul 27, 2023 |
| 18358591 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | §102§103 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18262438 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | KONOPKA, CATHERINE ANNE | 1635 | §112 | Final Rejection | 8d overdue | Pending | Jul 21, 2023 |
| 18247567 | METHODS FOR REDUCING APOCIII EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Non-Final OA | 4d overdue | Pending | Mar 31, 2023 |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 17998141 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Final Rejection | 67d overdue | Pending | Nov 07, 2022 |
| 17908135 | COMPOUNDS AND METHODS FOR MODULATING KCNQ2 | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Aug 30, 2022 |
| 17812401 | GENE THERAPY AND TARGETED DELIVERY OF CONJUGATED COMPOUNDS | GOLDBERG, JEANINE ANNE | 1682 | §103 | Final Rejection | — | Pending | Jul 13, 2022 |
| 17635096 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | VIVLEMORE, TRACY ANN | 1600 | §103 | Non-Final OA | — | Pending | Feb 14, 2022 |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 22, 2021 |
| 17424672 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | PERSONS, JENNA L | 1637 | §102§103DP | Non-Final OA | 66d overdue | Pending | Jul 21, 2021 |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Final Rejection | 10d overdue | Pending | Jul 09, 2021 |
| 17282335 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial